Skip to main content

Table 1 Patients baseline characteristic information

From: Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn’s disease: a Chinese real-world study

Index

Cohort (n = 19)

Age, y, mean ± SD

29.1 ± 9.1

Male, n (%)

11 (57.9)

Montreal classification, n (%)

Age at diagnosis

  < 16

0 (0)

 16–40

17 (89.5)

  > 40

2 (10.5)

Behavior

 B1

1052.6)

 B2

5 (26.3)

 B3

4 (21.1)

Location

 L1

2 (10.5)

 L2

1 (5.3)

 L3

16 (84.2)

 L4

0 (0)

Disease duration, y, mean ± SD

5.5 ± 4.7

BMI at diagnosis, mean ± SD

19.5 ± 2.4

EIM, n (%)

1 (5.3)

Perianal disease, n (%)

10 (52.6)

Previous biologics exposure, n (%)

17 (89.5)

 1

15 (78.9)

 2

1 (5.3)

 3

0 (0)

 4

1 (5.3)

Intestinal surgeries, n (%)

8 (42.1)

Concomitant drugs, n (%)

 Corticosteroid

1 (5.3)

 Thiopurine

1 (5.3)

UST administration interval, n (%)

 Q12w

14 (73.7)

 Q8w

5 (26.3)